Sensus Healthcare (NASDAQ:SRTS) Stock Price Crosses Below 50-Day Moving Average – Time to Sell?

Sensus Healthcare, Inc. (NASDAQ:SRTS) passed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $6.85 and traded as low as $5.36. Sensus Healthcare shares last traded at $5.38, with a volume of 280,695 shares trading hands.

Wall Street Analysts Forecast Growth

Several research firms have commented on SRTS. Maxim Group boosted their target price on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, November 15th. Lake Street Capital began coverage on Sensus Healthcare in a report on Friday, January 31st. They issued a “buy” rating and a $18.00 target price on the stock. Finally, HC Wainwright boosted their target price on Sensus Healthcare from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Monday, February 10th.

Sensus Healthcare Stock Down 3.2 %

The company has a fifty day simple moving average of $6.79 and a 200 day simple moving average of $6.84. The firm has a market capitalization of $88.18 million, a P/E ratio of 13.45 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. As a group, equities analysts expect that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC lifted its holdings in shares of Sensus Healthcare by 5.3% during the fourth quarter. Renaissance Technologies LLC now owns 430,934 shares of the company’s stock valued at $2,982,000 after purchasing an additional 21,600 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after purchasing an additional 88,953 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock valued at $1,039,000 after purchasing an additional 67,269 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Sensus Healthcare by 8.5% during the third quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after purchasing an additional 11,525 shares in the last quarter. Finally, Marshall Wace LLP increased its position in Sensus Healthcare by 99.6% during the fourth quarter. Marshall Wace LLP now owns 132,286 shares of the company’s stock valued at $915,000 after acquiring an additional 65,994 shares during the last quarter. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.